1. Home/
  2. Compounds/
  3. navitoclax:sorafenib (1:1 mol/mol)

navitoclax:sorafenib (1:1 mol/mol)


SourcesNames Used
CTRPv2navitoclax:sorafenib (1:1 mol/mol)
PharmacoGx navitoclax:sorafenib (1:1 mol/mol)

Cell lines tested with navitoclax:sorafenib (1:1 mol/mol)

835 cell lines have been tested with this compound, using data from 1 dataset(s).
2004 N/A CTRPv21
22RV1 prostate CTRPv21
23132-87 stomach CTRPv21
42-MG-BA central nervous system CTRPv21
5637 urinary tract CTRPv21
639-V urinary tract CTRPv21
647-V urinary tract CTRPv21
697 haematopoietic and lymphoid tissue CTRPv21
769-P kidney CTRPv21
786-0 kidney CTRPv21
Download CSV

Tissues tested with navitoclax:sorafenib (1:1 mol/mol)

25 tissues have been tested with this compound, using data from 1 dataset(s).
central nervous systemCTRPv247
urinary tractCTRPv222
biliary tractCTRPv26
haematopoietic and lymphoid tissueCTRPv2154
autonomic gangliaCTRPv213
Download CSV
Download Data as CSV

Top molecular features associated with response to navitoclax:sorafenib (1:1 mol/mol)

Feature TypeStandardized
Nominal ANOVA
mRNA ARHGAP33 CTRPv2 AAC 0.33 2e-20
mRNA TUBA1A CTRPv2 AAC 0.3 2e-14
mRNA RP11-729L2.2 CTRPv2 AAC 0.29 2e-14
mRNA SMAD4 CTRPv2 AAC 0.28 2e-14
mRNA GOLGA8M CTRPv2 AAC 0.26 2e-14
mRNA CELF4 CTRPv2 AAC 0.28 2e-14
mRNA PRR36 CTRPv2 AAC 0.28 6e-14
mRNA HDHD2 CTRPv2 AAC 0.28 7e-14
mRNA TIFAB CTRPv2 AAC 0.25 8e-14
mRNA CRMP1 CTRPv2 AAC 0.3 9e-14
Download CSV